September 14, 2020 -- Regeneron Pharmaceuticals and the University of Oxford have commenced a phase III clinical trial of potential treatments for COVID-19.
The Recovery open-label study is one of the largest COVID-19 trials in the world, according to Regeneron. It will compare the effectiveness of Regeneron's REGN-COV2 antibody therapy to the standard of care in patients hospitalized with COVID-19.
REGN-COV2 is also being evaluated in two other phase II and phase III trials to treat COVID-19 and prevent COVID-19 transmission among household members, according to Regeneron.
Already have an account? Sign in Here
To access all ScienceBoard content create a free account now: